Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Insulin-like growth factor 1 receptor inhibitor in combination with mitogen-activated protein kinases pathway inhibitor: ongoing clinical trials as of January 2013 (www.clinicaltrials.gov).
| IGF-1R inhibitor | MAPK pathway inhibitor | Phase | Indication | Trial ID |
|---|---|---|---|---|
| AMG479 (Ganitumab) |
MEK162 | lb/II | Selected advanced solid tumors | NCT01562899 |
IGF-1R, insulin-like growth factor 1 receptor; MAPK, mitogen-activated protein kinases.
